# Comparison of the efficacy of treatment with clobetasol propionate or bexarotene in early-stage mycosis fungoides

**Authors:** Aslı Aksu Çerman, Pinar Ozdemir Cetinkaya, Birgül Özkesici Kurt, Artun Kırker, İlknur Altunay

PMC · DOI: 10.1016/j.abd.2024.04.011 · Anais Brasileiros de Dermatologia · 2024-12-30

## TL;DR

This study compared two topical treatments for early-stage mycosis fungoides and found that bexarotene had longer-lasting effects but caused more irritation.

## Contribution

The study provides a direct comparison of bexarotene and clobetasol propionate efficacy and side effects in early-stage mycosis fungoides.

## Key findings

- Bexarotene had a longer median remission period (10.5 months) compared to clobetasol propionate (4 months).
- Bexarotene caused significantly more irritation symptoms than clobetasol propionate.
- Both treatments showed clinical effectiveness in early-stage mycosis fungoides.

## Abstract

There are few studies in the literature comparing the effectiveness of topical treatments in early-stage mycosis fungoides (MF).

It was aimed to evaluate the clinical efficacy, side effects and topical treatment compliance with bexarotene or clobetasol propionate in early-stage MF.

A total of 40 patients with stage IA-IB MF were enrolled in the study. Twenty patients were treated with 1% bexarotene gel and 20 patients were treated with 0.05% clobetasol propionate ointment.

In the bexarotene group, 11 patients (55%) had complete clinical response (CCR) and 5 patients (25%) had partial response (PR) while in the clobetasol propionate group, 10 patients (50%) had CCR and 9 patients (45%) had PR. The median duration of remission was 10.5 months in the bexarotene group and 4 months in the clobetasol propionate group. The remission period was statistically significantly longer in the bexarotene group (p = 0.032). Irritation symptoms were statistically significantly more common in the bexarotene group (p = 0.001).

The limitation of the study was its retrospective design.

Both topical bexarotene and topical clobetasol propionate were found to be effective in MF. Irritation symptoms were more common with topical bexarotene. Moreover, the remission period with topical bexarotene was significantly longer.

## Linked entities

- **Chemicals:** clobetasol propionate (PubChem CID 32798), bexarotene (PubChem CID 82146)
- **Diseases:** mycosis fungoides (MONDO:0009691)

## Full-text entities

- **Diseases:** MF (MESH:D009182), Irritation symptoms (MESH:D001523)
- **Chemicals:** bexarotene (MESH:D000077610), clobetasol propionate (MESH:D002990)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11962818/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11962818/full.md

## References

16 references — full list in the complete paper: https://tomesphere.com/paper/PMC11962818/full.md

---
Source: https://tomesphere.com/paper/PMC11962818